Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · IEX Real-Time Price · USD
2.415
-0.015 (-0.62%)
Apr 18, 2024, 3:16 PM EDT - Market open
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.
Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Sujal M. Patel |
Contact Details
Address: 2701 Eastlake Ave East Seattle, Washington 98102 United States | |
| Phone | 206-333-2001 |
| Website | nautilus.bio |
Stock Details
| Ticker Symbol | NAUT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001808805 |
| CUSIP Number | 63909J108 |
| ISIN Number | US63909J1088 |
| Employer ID | 98-1541723 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary and Director |
| Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist and Director |
| Anna Mowry | Chief Financial Officer and Treasurer |
| Mary E. Godwin | Senior Vice President of Operations |
| Matthew B. Murphy ESQ. | General Counsel |
| Chris Blessington | Vice President of Corporate Marketing and Communications |
| Gwen E. Weld | Chief People Officer |
| Nick A. Nelson | Chief Business Officer and Senior Vice President of Business Development |
| Dr. Subra Sankar Ph.D. | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2024 | EFFECT | Notice of Effectiveness |
| Mar 6, 2024 | 424B5 | Filing |
| Mar 4, 2024 | UPLOAD | Filing |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Dec 14, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 424B3 | Prospectus |